Outsourced AstraZeneca blockade not an issue for local COVID vaccine rollout

EU's decision to block 250,000 doses of AstraZeneca vaccine to Australia not an issue for covid vaccine rollout thanks to CSL local production

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Countries are holding on tight to their locally produced COVID-19 vaccines. As reported by ABC News, Italy and the European Union pulled the handbrake on the 250,000 AstraZeneca Plc (LSE: AZN) doses bound for Aussie shores. Australian politicians have stated that this is not an issue for our COVID-19 vaccine rollout.

As countries globally rush to get their hands on an approved vaccine, tensions have developed. Considering it is a potential ticket to returned economic growth, some are prioritising their own jurisdictions first and foremost.

CSL share price represented by hand in blue glove picks out a vial labelled 'covid-19 vaccine' from a row of vials

Image source: Getty Images

Not an issue for our vaccine rollout

Australian Health Minister Greg Hunt remarked that this decision by the EU would not impact Australia's COVID vaccine rollout:

This is one shipment from one country. This shipment was not factored into our distribution plan for the coming weeks. Domestic production starts with 1 million per week of deliveries from late March and is on track.

NSW Premier Gladys Berejiklian commented on the news this morning, emphasising the critical nature of local production:

I think what it demonstrates is the importance of us having a local supply. In the future, there will be supply issues. You need lots of jabs to be vaccinated properly, and therefore it's really important for us to be able to have our local supply.

The local supply these ministers refer to is coming from Australian-based CSL Ltd (ASX: CSL). Despite the emphasised importance of its operations this morning, the CSL share price is trending 2.6% lower. The biotech giant has now fallen for four consecutive sessions, erasing 8% in 4 days.

Domestic production of the AstraZeneca vaccine by CSL was expected to begin in early March. The company's production is anticipated to yield around 1 million doses per week by the end of March.

Ironic timing as first AstraZeneca vaccine administered

The EU's decision to block the 250,000 vaccines comes at an ironic time, as the first AstraZeneca dose was administered in Australia today.

An estimated 40 frontline staff at the Murray Bridge Hospital in South Australia will have received the vaccine by the end of the day.

Premier Berejiklian also mentioned that she believed media coverage should pivot to reporting on the number of vaccines administered rather than the number of new cases.

Furthermore, with the COVID vaccine rollout underway, the premier urged for the reopening of borders. Otherwise, she said, Australia could be left in the dust economically.

Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Five young people sit in a row having fun and interacting with their mobile phones.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a slightly sour end to the trading week this Friday.

Read more »

Two miners at a mine site on their tablets, with mining machinery behind them.
Share Fallers

Why has the Mineral Resources share price fallen 12% this week?

It’s been another tough week for Mineral Resources shareholders.

Read more »

Graphic depicting Australian economic activity.
ASX Share Market News

ASX 200 slips into the red after a positive start. Here's why

The benchmark index is seesawing again.

Read more »

Happy young couple riding a motorbike together.
Broker Notes

7 ASX 200 shares with reaffirmed buy ratings this week

Brokers retained a positive view on Santos, Zip, AMP, and other shares this week. 

Read more »

Sad man sitting at desk and grabbing his head as he looks at a laptop.
Broker Notes

Downgrade alert! 5 ASX 200 shares downgraded by experts this week

Brokers reduced their ratings on Wisetech, Harvey Norman, Ansell, and other stocks this week. 

Read more »

Woman holding several shopping bags.
Broker Notes

ASX retail shares are down 13% in 2026. Here's what Morgan Stanley is worried about

The sector has fallen hard, and concerns remain.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Broker Notes

Forget Xero shares! Broker tips this top ASX tech stock for 24% gains

This ASX tech stock has rocketed 143% in a year, and a leading broker forecasts another 24% of gains to…

Read more »

Young successful engineer, with blueprints, notepad, and digital tablet, observing the project implementation on construction site and in mine.
Broker Notes

This ASX nickel miner could jump 57%, Macquarie says

A resumption of dividends could also be on the cards.

Read more »